Human Insulin Injection 3ml 300IU Cartridge & 10ml 1000IU Vial

Human Insulin Injection 3ml 300IU Cartridge & 10ml 1000IU Vial: What the Published Guidance Says

Human and analogue insulins alongside the oral hypoglycaemics and cardiorenal-metabolic agents added to the WHO Model List in its September 2025 revision.

Human Insulin Injection 3ml 300IU Cartridge & 10ml 1000IU Vial is specified against its own monograph, pack size and market registration, so the guidance below is worth reading together with the Diabetes & Insulin range overview.

• The Model List details the insulin presentations and strengths Section 18.5.1 of the 24th WHO Model List (2025) lists human short-acting insulin as an injection solution of 40 IU/mL or 100 IU/mL in 10 mL vials and 100 IU/mL in 3 mL cartridges or pre-filled pens. Human intermediate-acting insulin is listed as an injection suspension in the same strengths, as compound insulin zinc suspension or isophane insulin. Long-acting and rapid-acting analogues are listed with glargine, degludec and detemir named among the therapeutic alternatives — a footnote notes that quality-assured biosimilars are included. WHO eEML — Medicines for diabetes
• SGLT2 inhibitors are on the Model List Section 18.5.2 lists empagliflozin as a 10 mg and 25 mg tablet for type 2 diabetes mellitus, with canagliflozin and dapagliflozin named as therapeutic equivalents. WHO eEML — Medicines for diabetes
• The scale of the access problem WHO reports that more than 800 million people were living with diabetes in 2022, with half going untreated, and that more than one billion people worldwide are affected by obesity with rates rising fastest in low- and middle-income countries. WHO — Essential medicines list updated to include key cancer and diabetes treatments (5 Sep 2025)

Each point above is reproduced because it has a practical consequence for Human Insulin Injection 3ml 300IU Cartridge & 10ml 1000IU Vial: the strength you can register, the pack you can release, or the wording permitted on the label. Your national prescribing information always takes precedence.

How Human Insulin Injection 3ml 300IU Cartridge & 10ml 1000IU Vial Is Tested and Released

Products are manufactured and tested against USP, EP, BP and CP monographs, with incoming raw-material inspection, in-process monitoring and full finished-product testing.

Release testing for Human Insulin Injection 3ml 300IU Cartridge & 10ml 1000IU Vial follows the monograph you nominate — USP, EP, BP or CP. If the presentation is not covered by a monograph, the specification is frozen in writing with your quality team before the batch is manufactured.

Standardised GMP production workshops with an independent R&D laboratory and a complete quality-inspection centre.

Release testing on this presentation is built around:

• Testing for description and identification
• Testing for assay of the active substance
• Testing for related substances and impurities
• Testing for dissolution or release profile (solid oral forms)
• Testing for uniformity of dosage units
• Testing for water content and pH where applicable

COA, HPLC and GC data, DMF and dossier packages, plus registration support documents for national marketing-authorisation filings.

How Human Insulin Injection 3ml 300IU Cartridge & 10ml 1000IU Vial Is Packed, Labelled and Shipped

• Pack size: 3mL glass cartridge (for use with compatible insulin pen devices) & 10mL type I glass vial with rubber stopper and aluminum seal. Non-standard pack sizes can be quoted against your artwork.
• Storage: Unopened: Store refrigerated at 2°C to 8°C, protected from light. Do NOT freeze. In-use (opened): Store at room temperature (below 25°C) for up to 28 days, away from direct heat and light. Discard after 28 days even if unused..
• Shelf life: 36 months (unopened, refrigerated). Stability data for the marketed pack is included in the dossier.
• Labelling: artwork can be produced in English, Arabic, French, Russian and Spanish, with your own brand and language mix, subject to the labelling rules of the destination market.
• Export: GMP certificate, COA, certificate of origin, packing list and, where required, the free-sale or marketing authorisation certificate from the country of manufacture.

Regulatory Support for Human Insulin Injection 3ml 300IU Cartridge & 10ml 1000IU Vial

The legal manufacturer named on every document for Human Insulin Injection 3ml 300IU Cartridge & 10ml 1000IU Vial is Sinophare Bio-technology Co., Ltd., DML Number Jin20160068 (medicines) and Jin20160069 (paracetamol API).. The same entity appears on the GMP certificate and on the dossier submitted to your regulator.

• Method validation, stability protocol and the shelf-life justification for the marketed pack.
• Answers to authority questions during assessment, handled by the regulatory contact who prepared the file.
• Tender and framework documentation, including pre-qualification questionnaires and sample logistics.
• Artwork and mock-up approval pack, showing the carton, label and leaflet exactly as they will be printed for your market.
• Batch manufacturing and packaging records released for inspection on request during supplier audits.

Human Insulin Injection 3ml 300IU Cartridge & 10ml 1000IU Vial is presented here against medicines for diabetes listed in the WHO Model List. Inclusion in an essential-medicines list does not authorise sale in any particular country — the marketing authorisation for that market is a separate step.